COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 12 FDA records to the applicant name Life Technologies Corporation. The collection includes 1 510(k) clearance. It includes 1 original PMA approval. 7 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 2, 2025 to Nov 4, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code PQP appears in 11 of the 12 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P240040, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 7335 Executive Way, Frederick, MD, 21704. Recorded on P240040/S008, decision dated Nov 4, 2026.
Device categories in this collection
Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System; High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids.
Changes described in PMA records
The FDA recorded approval on 2026-11-04 for P240040/S008, a supplement to the Oncomine Dx Express Test held by Life Technologies Corporation. The supplement is classified as a real-time process submission with a recorded reason of change to design, components, specifications or materials. The device category is a next generation sequencing oncology panel for somatic or germline variant detection, under product code PQP in the pathology specialty.
The recorded scope is narrow: approval covers Genexus Dx Software Security Patch version 6.8.2.2, intended to address vulnerabilities discovered in the Genexus Dx Software. This is a software component change within the existing application, not a new approval of the whole test system, and the source does not describe analytical or clinical performance data, affected assay functions, or the nature of the vulnerabilities. Whether the patch alters test performance or requires customer action is not stated in the available record.
FDA approval-order wording
Approval for Genexus Dx Software Security Patch version 6.8.2.2 to address the vulnerabilities discovered on the Genexus Dx Software.
Nov 4, 2026 · Real-Time ProcessThis FDA record documents the September 9, 2026 approval of supplement S005 to PMA P240040 for Life Technologies Corporation. The supplement, filed under the Panel Track with a labeling-change reason, expands the approved indications for use to add a companion diagnostic indication. That indication covers detection of ERBB2/HER2 activating mutations, specified as single nucleotide variants in exons 18–21 within the tyrosine kinase domain plus exon 20 insertions, in patients with non-small cell lung cancer.
The changed item is the indications statement of the device, a next-generation sequencing oncology panel for somatic or germline variant detection under product code PQP and the Pathology specialty. The source statement links the added indication to identifying NSCLC patients who may benefit from treatment with HYRNUO (sevabertinib). This supplement modifies the existing P240040 approval rather than approving the whole system anew; the record does not describe the panel's other content, performance characteristics, or original scope beyond the identifier.
FDA approval-order wording
Approval to expand the indications for use to include a companion diagnostic (CDx) indication for the detection of ERBB2/HER2 activating mutations (SNVs in exons 18-21 within the tyrosine kinase domain and exon 20 insertions) in patients with non-small cell lung cancer (NSCLC) who may benefit from treatment with HYRNUO (sevabertinib).
Sep 9, 2026 · Panel TrackFDA’s recorded scope: process changes for implementation of two new analytical QC assays
Jun 8, 2026 · 30-Day NoticeFDA’s recorded scope: approval for an increase in quality control sampling of components during the QC release process
Mar 4, 2026 · Special (Immediate Track)FDA’s recorded scope: approval of additional QC steps during the device component manufacturing process
Nov 21, 2025 · Special (Immediate Track)Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.